E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic myeloid leukemia (CML) in chronic phase (CP) |
|
E.1.1.1 | Medical condition in easily understood language |
Chronic myeloid leukemia is a type of cancer that starts in certain blood-forming cells of the bone marrow. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10009015 |
E.1.2 | Term | Chronic myeloid leukemia |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The study will investigate in newly diagnosed CP-CML patients the efficacy of NIL frontline therapy vs IM followed by switch to NIL in the case of absence of optimal response as defined by the ELN criteria using two primary end-points: - To evaluate the rates of molecular response (MR4.5) at 24 months - To evaluate the rate of patients who remain in sustained treatment free remission (≥MR3.0) without molecular relapse 12 months after entering the TFR phase. The molecular relapse is defined as loss of MMR, or confirmed loss of MR3.0
|
|
E.2.2 | Secondary objectives of the trial |
Monitoring the molecular response. Progression-free survival (PFS) in the two arms of the study. Overall Survival in the two arms of the study. Rates of major molecular response (MR3.0) during the study in the two arms of the study. The dynamics of molecular response The relationship between baseline characteristics and the primary objectives The relationship between early molecular response and the primary objectives To assess the safety profile of both arms. To determine the rate and the time-distribution of the discontinuation causes of the first-line TKI. To investigate quality of life (QoL) differences between treatment arms over time
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Quality of life To investigate quality of life differences between treatment arms over time
Translational research Deep phenotypic and molecular characterization of INDIVIDUAL LSC within the LSC pool of newly diagnosed CML patients; Deep understanding of the cellular pathways involved in CML LSC persistence and genomic instability; Deep understanding of the physio-pathogenesis of CML by detecting pre-existing mutated (DNMT3A) ancestral clones, leading to leukemia by the addition of following alterations (Bcr-Abl); To define BM microenvironment markers that nurture and determine stem cell fate in leukemia associated-niches; To define MSC’s genetic profile in CML patients; To evaluate the role of BM molecular microenvironment underling the variable degree of response to TKI treatment in patients with CP of CML vs. patients with advanced phase CML; To verify the prognostic value of the biological factors that have been assessed in vitro experiments by designing an in vivo mouse model; Flow-cytometry quantification and monitoring of peripheral blood CML LSCs during Sustrenim Study.
|
|
E.3 | Principal inclusion criteria |
•Patients with a confirmed diagnosis of BCR/ABL+ CML in chronic phase o Documented chronic phase CML must meet all the following criteria: < 15% blasts in peripheral blood < 30% blasts plus promyelocytes in peripheral blood < 20% basophils in the peripheral blood ≥ 100 x 109/L (≥ 100,000/mm3) platelets •Age ≥18 •ECOG performance status of 0-2 •Evidence of typical BCR-ABL transcripts which are amenable to standardized RQ-PCR •Adequate end organ function as defined by: o Total bilirubin < 1.5 x ULN (ULN = upper limit of normal in a local institution lab). Does not apply to patients with isolated hyperbilirubinemia (e.g., Gilbert’s disease) grade < 3 o SGOT (AST) and SGPT (ALT) ≤ 3 x ULN o Serum amylase and lipase ≤ 2 x ULN o Alkaline phosphatase ≤ 2.5 x ULN o Serum creatinine < 1.5 x ULN •Written informed consent prior to any study procedures
|
|
E.4 | Principal exclusion criteria |
•Previous treatment with BCR-ABL inhibitors for more than 30 days. •Expression of any atypical BCR-ABL transcripts, instead of the classical P210-encoding type with the e13a2 or the e14a2 junction at screening. •Previous anticancer agents (hydroxyurea, anagrelide, interferon) for CML for more than three months. •Poorly controlled diabetes mellitus (defined as HbA1c >8%) •Prior documented history of coronary heart disease, including myocardial infarction, coronary bypass, coronary stent, and symptomatic angina as defined at page 30 in Exclusion Criteria. •Uncontrolled hypertension •History of peripheral arterial occlusive disease. •History of acute pancreatitis within 12 months of study entry, or a past medical history of chronic pancreatitis. •Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers which cannot be either discontinued or switched to a different medication prior to starting study drug. •Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and for which cannot be either safely discontinued or switched to a different medication prior to starting study drug. •Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment. •Patients unable to understand and to comply with study instructions and requirements. •Refusal to give informed consent.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
- To evaluate the rates of molecular response (MR4.5) at 24 months - To evaluate the rate of patients who remain in sustained treatment free remission (≥MR3.0) without molecular relapse 12 months after entering the TFR phase.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At 24 months for the rates of molecular response (MR4.5) and at 12 months after entering the TFR phase for the rate of patients who remain in sustained treatment free remission (≥MR3.0) without molecular relapse. |
|
E.5.2 | Secondary end point(s) |
- To determine the depth of molecular response by 4 years. - To estimate progression-free survival (PFS) in the two arms of the study at 60 months. - To estimate the Overall Survival in the two arms of the study at 60 months. - To determine the rates of major molecular response (MR3.0) at 1, 2, 3, and 4 year in the two arms of the study. - The dynamics of molecular response - The relationship between baseline characteristics and the achievement of MR4.5 (after treatment NIL frontline therapy vs IM followed by switch to NIL) and the sustained treatment free remission rate (≥MR3.0); - The relationship between early molecular response and the achievement of MR4.5 (after treatment NIL frontline therapy vs IM followed by switch to NIL) and the sustained treatment free remission rate (≥MR3.0) - To assess the safety profile of either NIL and IM arms. - To determine the rate and the time-distribution of the discontinuation of the first-line TKI, for side-effects, toxicity and AEs. - To investigate quality of life (QoL) differences between treatment arms over time.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 75 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 8 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 8 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |